{
    "clinical_study": {
        "@rank": "77192", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "description": "Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program"
            }, 
            {
                "arm_group_label": "Validation cohort", 
                "description": "Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program."
            }, 
            {
                "arm_group_label": "Pilot cohort", 
                "description": "Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program."
            }
        ], 
        "brief_summary": {
            "textblock": "Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to\n      achieve sustained virological response (SVR). The aim of our study is to evaluate the\n      efficacy of a multidisciplinary support program (MSP) in adherence to and efficacy of\n      pegylated interferon alfa-2a and ribavirin compared to the conventional approach. We\n      assessed 447 patients with CHC receiving antiviral treatment distributed into 3 groups:\n      control group (recruited 2002-2004, n= 147), MSP-pilot group (recruited 2005-2006, n=131),\n      and MSP-validation group (recruited 2007-2009, n=169)."
        }, 
        "brief_title": "Multidisciplinary Support Program in Chronic Hepatitis C", 
        "completion_date": {
            "#text": "January 2010", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to\n      achieve sustained virological response (SVR). The aim of our study is to evaluate the\n      efficacy of a multidisciplinary support program (MSP) in adherence to and efficacy of\n      pegylated interferon alfa-2a and ribavirin compared to the conventional approach. We\n      assessed 447 patients with CHC receiving antiviral treatment distributed into 3 groups:\n      control group (follow-up 2002-2004, n= 147), MSP-pilot group (follow-up 2005-2006, n=131),\n      and MSP-validation group (follow-up 2007-2009, n=169).A cost-effectiveness analysis was\n      performed using a Markov model."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with chronic hepatitis C eligible to receive antiviral treatment.\n\n        Exclusion Criteria:\n\n          -  Patients who had undergone previous antiviral treatment, those with human\n             immunodeficiency virus (HIV) or hepatitis B virus (HBV) co-infection, and individuals\n             included in other treatment protocols."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Chronic hepatitis C virus infection (CHC)"
            }
        }, 
        "enrollment": {
            "#text": "447", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850745", 
            "org_study_id": "HMAR-MSP-CHC"
        }, 
        "intervention": {
            "arm_group_label": [
                "Pilot cohort", 
                "Validation cohort"
            ], 
            "description": "Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.", 
            "intervention_name": "Multidisciplinary support program", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Peginterferon alfa-2a"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Chronic hepatitis C virus infection (CHC)", 
        "lastchanged_date": "May 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08003"
                }, 
                "name": "Hospital del Mar"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "3", 
        "official_title": "Evaluation of a multid\u00ecsciplinary Support Program in the Adherence and Efficacy of Peginterferon Alfa-2a and Ribavirin Therapy in Chronic Hepatitis C.", 
        "overall_official": {
            "affiliation": "Hsopital del Mar, Parc de Salut MAR", 
            "last_name": "Ricard Sola, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Adherent patients were defined as those receiving equal or more than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during equal o more than 80% of duration treatment (48 weeks).\nNon-adherent patients were defined as those receiving less than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during less than 80% of duration treatment (48 weeks).", 
            "measure": "Adherence to treatment", 
            "safety_issue": "No", 
            "time_frame": "48 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850745"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary efficacy end point was to evaluate the sustained virological response (SVR) of antiviral treatment.\nSVR was defined as undetectable hepatitis C virus viral load (<15 IU/ml) 24 weeks after treatment completion.\nNon-SVR was defined as detectable hepatitis C virus viral load (>15 IU/ml) 24 weeks after treatment completion.", 
            "measure": "Efficacy of treatment measured by sustained virological response", 
            "safety_issue": "No", 
            "time_frame": "baseline and 72 weeks"
        }, 
        "source": "Parc de Salut Mar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Parc de Salut Mar", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2003", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}